Search results for: 'nanoparticl pharma'

This issue of the Nanotechnology Opportunity Engine profiles significant advances in nanotechnology for various industrial applications. The featured innovations include Self-cleaning Nanocoatings for Enhanced Photovoltaic Efficiency, Protective Nanocoatings for Electronics in Renewable Energy Applications, Protective Nanocoatings for High-performa...

With the growing preference for a patient-centric care delivery approach, the pharma industry follows a robust step-by-step approach towards market commercialization, with a clear understanding of the market stakeholders, segments, as well as post-launch forecasts to create seamless go-to-market strategies. To cater to the ever-evolving market land...

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promis...

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

This research study provides a comprehensive analysis of the evolving landscape for managing complex effluents from critical sectors of pharmaceuticals and healthcare facilities, such as hospitals. It examines the escalating wastewater burden resulting from the expansion of healthcare infrastructure and the impact of stringent regulations across ma...

Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape in this analysis. The study period is 2021 2028, with 2023 as the base year and 2024 2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and the...

This research service provides an overview of the pharma-biotech industry in terms of critical success factors and alliance management.